Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493305 | 1.00 | ITGB3 (0.50) | ITGB3ITGA2BAKR1B1GRIN2BCYP1A2 | |
| SCHEMBL10508397 | 0.85 | PNMT (0.48) | AKR1B1GRIN2BMAPTADRA2APNMT | |
| SCHEMBL6505635 | 0.83 | MAPT (0.44) | ALDH1A1MAPT | |
| SCHEMBL16650443 | 0.83 | PNMT (0.46) | AKR1B1GRIN2BALDH1A1MAPTADRA2A | |
| SCHEMBL7390944 | 0.83 | GRIN2B (0.41) | GRIN2BALDH1A1MAPTADRA2APNMT | |
| SCHEMBL8426665 | 0.81 | PNMT (0.41) | AKR1B1GRIN2BALDH1A1MAPTADRA2A | |
| SCHEMBL4673780 | 0.80 | GRIN2B (0.41) | AKR1B1GRIN2BMAPTADRA2APNMT | |
| SCHEMBL5846777 | 0.80 | GRIN2B (0.41) | AKR1B1GRIN2BMAPTADRA2APNMT | |
| SCHEMBL4673771 | 0.80 | GRIN2B (0.41) | AKR1B1GRIN2BMAPTADRA2APNMT | |
| SCHEMBL4670515 | 0.80 | GRIN2B (0.41) | AKR1B1GRIN2BMAPTADRA2APNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855833-B2 | Methods for producing amino substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040225137-A1 | Methods for producing amino substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040044225-A1 | Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2001094330-A2 | METHODS FOR PRODUCING AMINO SUBSTITUTED CHROMANES | COR THERAPEUTICS, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001092249-A2 | CHIRAL AND ACHIRAL SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND THEIR DERIVATIVES | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044225-A1 | Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives | ACAT2, ACACA, COASY | ITGB3 203/4885ITGA2B 395/4885AKR1B1 391/4885 |
| US-20040225137-A1 | Methods for producing amino substituted chromanes and intermediates thereof | PFKP, PDGFRA, TBXAS1 | ITGB3 392/4885ITGA2B 777/4885AKR1B1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.